Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Background Patients with moderate to severe allergic rhinitis (AR) who are treated according to the current rhinitis management guidelines may be inadequately controlled. These patients are at risk of serious comorbidities, such as asthma and chronic sinusitis. These symptoms, sneezing and an itchy,...

Full description

Saved in:
Bibliographic Details
Published in:American journal of rhinology & allergy 2020-03, Vol.34 (2), p.196-208
Main Authors: Yu, Chenjie, Wang, Kaijian, Cui, Xinyan, Lu, Ling, Dong, Jianfei, Wang, Maohua, Gao, Xia
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c337t-ecdbcbc59c1ea1170e0175ca4b686f08e4a03254826f540ac3f229f184a3e8233
cites cdi_FETCH-LOGICAL-c337t-ecdbcbc59c1ea1170e0175ca4b686f08e4a03254826f540ac3f229f184a3e8233
container_end_page 208
container_issue 2
container_start_page 196
container_title American journal of rhinology & allergy
container_volume 34
creator Yu, Chenjie
Wang, Kaijian
Cui, Xinyan
Lu, Ling
Dong, Jianfei
Wang, Maohua
Gao, Xia
description Background Patients with moderate to severe allergic rhinitis (AR) who are treated according to the current rhinitis management guidelines may be inadequately controlled. These patients are at risk of serious comorbidities, such as asthma and chronic sinusitis. These symptoms, sneezing and an itchy, runny, stuffy nose, may have a negative impact on patients’ daily functioning. Omalizumab is being developed as a new choice for the treatment of AR. We therefore undertook a meta-analysis to assess the efficacy and safety of omalizumab in the treatment of AR. Methods We systematically searched PubMed, Cochrane Library, and MEDLINE databases for randomized controlled studies on the treatment of AR with omalizumab. Our evaluation outcomes were symptom scores, medication efficacy, combined symptom and medication scores, and adverse events. We descriptively summarized and quantitatively synthesized original data to evaluate the efficacy and safety of omalizumab in the treatment of AR by using Stata12.0 software for meta-analyses. Results The results of our meta-analysis showed that there were statistically significant differences between the omalizumab group and the control group in the following aspects: daily nasal symptom score (standardized mean difference [SMD] = –0.443, 95% confidence interval [CI]: –0.538 to –0.347, P 
doi_str_mv 10.1177/1945892419884774
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2311637301</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1945892419884774</sage_id><sourcerecordid>2311637301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-ecdbcbc59c1ea1170e0175ca4b686f08e4a03254826f540ac3f229f184a3e8233</originalsourceid><addsrcrecordid>eNp1UU1P3DAUtKpWhdLeOSEfewn1VxKH22pFoRIVEmzP0Yv3GYycBGynVfgf_b84XbqHSj3N07yZ0dM8Qo45O-W8rr_wRpW6EYo3Wqu6Vm_I4UIVupHi7X4W6oB8iPGBsUqVir8nB5JXtWCCHZLfa-8GZ8DTc2szmpnCsKW3YDHNdLT0ugfvnqceOuoGmu6RbgJC6nFIy3rlPYY7Z-jNfc5JLp7RFb2dY8Ie0kLjT4e__mR-xwQFDODn6OLivcns2Ltn3NL9FZvgwMeP5J3NgJ9e8Yj8-Hq-WV8WV9cX39arq8JIWacCzbYznSkbwxFyIQwZr0sDqqt0ZZlGBUyKUmlR2VIxMNIK0ViuFUjUQsoj8nmX-xjGpwljansXDXoPA45TbIXkvJK1ZDxL2U5qwhhjQNs-BtdDmFvO2uUZ7b_PyJaT1_Sp63G7N_xtPwuKnSDCHbYP4xRyO_H_gS-jt5KF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2311637301</pqid></control><display><type>article</type><title>Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials</title><source>SAGE</source><creator>Yu, Chenjie ; Wang, Kaijian ; Cui, Xinyan ; Lu, Ling ; Dong, Jianfei ; Wang, Maohua ; Gao, Xia</creator><creatorcontrib>Yu, Chenjie ; Wang, Kaijian ; Cui, Xinyan ; Lu, Ling ; Dong, Jianfei ; Wang, Maohua ; Gao, Xia</creatorcontrib><description><![CDATA[Background Patients with moderate to severe allergic rhinitis (AR) who are treated according to the current rhinitis management guidelines may be inadequately controlled. These patients are at risk of serious comorbidities, such as asthma and chronic sinusitis. These symptoms, sneezing and an itchy, runny, stuffy nose, may have a negative impact on patients’ daily functioning. Omalizumab is being developed as a new choice for the treatment of AR. We therefore undertook a meta-analysis to assess the efficacy and safety of omalizumab in the treatment of AR. Methods We systematically searched PubMed, Cochrane Library, and MEDLINE databases for randomized controlled studies on the treatment of AR with omalizumab. Our evaluation outcomes were symptom scores, medication efficacy, combined symptom and medication scores, and adverse events. We descriptively summarized and quantitatively synthesized original data to evaluate the efficacy and safety of omalizumab in the treatment of AR by using Stata12.0 software for meta-analyses. Results The results of our meta-analysis showed that there were statistically significant differences between the omalizumab group and the control group in the following aspects: daily nasal symptom score (standardized mean difference [SMD] = –0.443, 95% confidence interval [CI]: –0.538 to –0.347, P < .001); daily ocular symptom score (SMD = –0.385, 95% CI: –0.5 to –0.269, P < .001); daily nasal medication symptom scores (SMD = –0.421, 95% CI: –0.591 to –0.251, P < .001); proportion of days of emergency drug use (risk ratio [RR] = 0.488, 95% CI: 0.307 to 0.788, P < .005); rhinoconjunctivitis-specific quality of life questionnaire (SMD = –0.286, 95% CI: –0.418 to –0.154, P < .001); and overall evaluation (RR = 1.435, 95% CI: 1.303–1.582, P < .001). There was no statistically significant difference in safety indicator: adverse events (RR = 1.026, 95% CI: 0.916–1.150, P = .655). Conclusion Omalizumab is effective and relatively safe in patients with AR; omalizumab used in conjunction with special immunotherapy has shown promising results, especially in reducing adverse events.]]></description><identifier>ISSN: 1945-8924</identifier><identifier>EISSN: 1945-8932</identifier><identifier>DOI: 10.1177/1945892419884774</identifier><identifier>PMID: 31672020</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><ispartof>American journal of rhinology &amp; allergy, 2020-03, Vol.34 (2), p.196-208</ispartof><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-ecdbcbc59c1ea1170e0175ca4b686f08e4a03254826f540ac3f229f184a3e8233</citedby><cites>FETCH-LOGICAL-c337t-ecdbcbc59c1ea1170e0175ca4b686f08e4a03254826f540ac3f229f184a3e8233</cites><orcidid>0000-0002-1672-544X ; 0000-0002-6734-6247</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31672020$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yu, Chenjie</creatorcontrib><creatorcontrib>Wang, Kaijian</creatorcontrib><creatorcontrib>Cui, Xinyan</creatorcontrib><creatorcontrib>Lu, Ling</creatorcontrib><creatorcontrib>Dong, Jianfei</creatorcontrib><creatorcontrib>Wang, Maohua</creatorcontrib><creatorcontrib>Gao, Xia</creatorcontrib><title>Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials</title><title>American journal of rhinology &amp; allergy</title><addtitle>Am J Rhinol Allergy</addtitle><description><![CDATA[Background Patients with moderate to severe allergic rhinitis (AR) who are treated according to the current rhinitis management guidelines may be inadequately controlled. These patients are at risk of serious comorbidities, such as asthma and chronic sinusitis. These symptoms, sneezing and an itchy, runny, stuffy nose, may have a negative impact on patients’ daily functioning. Omalizumab is being developed as a new choice for the treatment of AR. We therefore undertook a meta-analysis to assess the efficacy and safety of omalizumab in the treatment of AR. Methods We systematically searched PubMed, Cochrane Library, and MEDLINE databases for randomized controlled studies on the treatment of AR with omalizumab. Our evaluation outcomes were symptom scores, medication efficacy, combined symptom and medication scores, and adverse events. We descriptively summarized and quantitatively synthesized original data to evaluate the efficacy and safety of omalizumab in the treatment of AR by using Stata12.0 software for meta-analyses. Results The results of our meta-analysis showed that there were statistically significant differences between the omalizumab group and the control group in the following aspects: daily nasal symptom score (standardized mean difference [SMD] = –0.443, 95% confidence interval [CI]: –0.538 to –0.347, P < .001); daily ocular symptom score (SMD = –0.385, 95% CI: –0.5 to –0.269, P < .001); daily nasal medication symptom scores (SMD = –0.421, 95% CI: –0.591 to –0.251, P < .001); proportion of days of emergency drug use (risk ratio [RR] = 0.488, 95% CI: 0.307 to 0.788, P < .005); rhinoconjunctivitis-specific quality of life questionnaire (SMD = –0.286, 95% CI: –0.418 to –0.154, P < .001); and overall evaluation (RR = 1.435, 95% CI: 1.303–1.582, P < .001). There was no statistically significant difference in safety indicator: adverse events (RR = 1.026, 95% CI: 0.916–1.150, P = .655). Conclusion Omalizumab is effective and relatively safe in patients with AR; omalizumab used in conjunction with special immunotherapy has shown promising results, especially in reducing adverse events.]]></description><issn>1945-8924</issn><issn>1945-8932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1UU1P3DAUtKpWhdLeOSEfewn1VxKH22pFoRIVEmzP0Yv3GYycBGynVfgf_b84XbqHSj3N07yZ0dM8Qo45O-W8rr_wRpW6EYo3Wqu6Vm_I4UIVupHi7X4W6oB8iPGBsUqVir8nB5JXtWCCHZLfa-8GZ8DTc2szmpnCsKW3YDHNdLT0ugfvnqceOuoGmu6RbgJC6nFIy3rlPYY7Z-jNfc5JLp7RFb2dY8Ie0kLjT4e__mR-xwQFDODn6OLivcns2Ltn3NL9FZvgwMeP5J3NgJ9e8Yj8-Hq-WV8WV9cX39arq8JIWacCzbYznSkbwxFyIQwZr0sDqqt0ZZlGBUyKUmlR2VIxMNIK0ViuFUjUQsoj8nmX-xjGpwljansXDXoPA45TbIXkvJK1ZDxL2U5qwhhjQNs-BtdDmFvO2uUZ7b_PyJaT1_Sp63G7N_xtPwuKnSDCHbYP4xRyO_H_gS-jt5KF</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Yu, Chenjie</creator><creator>Wang, Kaijian</creator><creator>Cui, Xinyan</creator><creator>Lu, Ling</creator><creator>Dong, Jianfei</creator><creator>Wang, Maohua</creator><creator>Gao, Xia</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1672-544X</orcidid><orcidid>https://orcid.org/0000-0002-6734-6247</orcidid></search><sort><creationdate>202003</creationdate><title>Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials</title><author>Yu, Chenjie ; Wang, Kaijian ; Cui, Xinyan ; Lu, Ling ; Dong, Jianfei ; Wang, Maohua ; Gao, Xia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-ecdbcbc59c1ea1170e0175ca4b686f08e4a03254826f540ac3f229f184a3e8233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Chenjie</creatorcontrib><creatorcontrib>Wang, Kaijian</creatorcontrib><creatorcontrib>Cui, Xinyan</creatorcontrib><creatorcontrib>Lu, Ling</creatorcontrib><creatorcontrib>Dong, Jianfei</creatorcontrib><creatorcontrib>Wang, Maohua</creatorcontrib><creatorcontrib>Gao, Xia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of rhinology &amp; allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Chenjie</au><au>Wang, Kaijian</au><au>Cui, Xinyan</au><au>Lu, Ling</au><au>Dong, Jianfei</au><au>Wang, Maohua</au><au>Gao, Xia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials</atitle><jtitle>American journal of rhinology &amp; allergy</jtitle><addtitle>Am J Rhinol Allergy</addtitle><date>2020-03</date><risdate>2020</risdate><volume>34</volume><issue>2</issue><spage>196</spage><epage>208</epage><pages>196-208</pages><issn>1945-8924</issn><eissn>1945-8932</eissn><abstract><![CDATA[Background Patients with moderate to severe allergic rhinitis (AR) who are treated according to the current rhinitis management guidelines may be inadequately controlled. These patients are at risk of serious comorbidities, such as asthma and chronic sinusitis. These symptoms, sneezing and an itchy, runny, stuffy nose, may have a negative impact on patients’ daily functioning. Omalizumab is being developed as a new choice for the treatment of AR. We therefore undertook a meta-analysis to assess the efficacy and safety of omalizumab in the treatment of AR. Methods We systematically searched PubMed, Cochrane Library, and MEDLINE databases for randomized controlled studies on the treatment of AR with omalizumab. Our evaluation outcomes were symptom scores, medication efficacy, combined symptom and medication scores, and adverse events. We descriptively summarized and quantitatively synthesized original data to evaluate the efficacy and safety of omalizumab in the treatment of AR by using Stata12.0 software for meta-analyses. Results The results of our meta-analysis showed that there were statistically significant differences between the omalizumab group and the control group in the following aspects: daily nasal symptom score (standardized mean difference [SMD] = –0.443, 95% confidence interval [CI]: –0.538 to –0.347, P < .001); daily ocular symptom score (SMD = –0.385, 95% CI: –0.5 to –0.269, P < .001); daily nasal medication symptom scores (SMD = –0.421, 95% CI: –0.591 to –0.251, P < .001); proportion of days of emergency drug use (risk ratio [RR] = 0.488, 95% CI: 0.307 to 0.788, P < .005); rhinoconjunctivitis-specific quality of life questionnaire (SMD = –0.286, 95% CI: –0.418 to –0.154, P < .001); and overall evaluation (RR = 1.435, 95% CI: 1.303–1.582, P < .001). There was no statistically significant difference in safety indicator: adverse events (RR = 1.026, 95% CI: 0.916–1.150, P = .655). Conclusion Omalizumab is effective and relatively safe in patients with AR; omalizumab used in conjunction with special immunotherapy has shown promising results, especially in reducing adverse events.]]></abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>31672020</pmid><doi>10.1177/1945892419884774</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-1672-544X</orcidid><orcidid>https://orcid.org/0000-0002-6734-6247</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1945-8924
ispartof American journal of rhinology & allergy, 2020-03, Vol.34 (2), p.196-208
issn 1945-8924
1945-8932
language eng
recordid cdi_proquest_miscellaneous_2311637301
source SAGE
title Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A10%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Efficacy%20and%20Safety%20of%20Omalizumab%20in%20the%20Treatment%20of%20Allergic%20Rhinitis:%20A%20Systematic%20Review%20and%20Meta-analysis%20of%20Randomized%20Clinical%20Trials&rft.jtitle=American%20journal%20of%20rhinology%20&%20allergy&rft.au=Yu,%20Chenjie&rft.date=2020-03&rft.volume=34&rft.issue=2&rft.spage=196&rft.epage=208&rft.pages=196-208&rft.issn=1945-8924&rft.eissn=1945-8932&rft_id=info:doi/10.1177/1945892419884774&rft_dat=%3Cproquest_cross%3E2311637301%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c337t-ecdbcbc59c1ea1170e0175ca4b686f08e4a03254826f540ac3f229f184a3e8233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2311637301&rft_id=info:pmid/31672020&rft_sage_id=10.1177_1945892419884774&rfr_iscdi=true